Michael J. Detke - 06 Jul 2021 Form 4 Insider Report for Cortexyme, Inc. (QNCX)

Role
Chief Medical Officer
Signature
/s/ Caryn Gordon McDowell, Attorney-in-Fact for Michael J. Detke, M.D.
Issuer symbol
QNCX
Transactions as of
06 Jul 2021
Net transactions value
-$3,081,272
Form type
4
Filing time
07 Jul 2021, 20:38:59 UTC
Next filing
12 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QNCX Common Stock Options Exercise $28,098 +12,600 +45% $2.23 40,861 06 Jul 2021 Direct
transaction QNCX Common Stock Sale $1,726,484 -32,313 -79% $53.43* 8,548 06 Jul 2021 Direct F1, F2
transaction QNCX Common Stock Sale $445,297 -8,260 -97% $53.91* 288 06 Jul 2021 Direct F1, F3
transaction QNCX Common Stock Sale $15,843 -288 -100% $55.01* 0 06 Jul 2021 Direct F1
transaction QNCX Common Stock Options Exercise $38,802 +17,400 $2.23 17,400 07 Jul 2021 Direct
transaction QNCX Common Stock Sale $209,446 -3,934 -23% $53.24* 13,466 07 Jul 2021 Direct F1, F4
transaction QNCX Common Stock Sale $89,602 -1,648 -12% $54.37* 11,818 07 Jul 2021 Direct F1, F5
transaction QNCX Common Stock Sale $241,069 -4,353 -37% $55.38* 7,465 07 Jul 2021 Direct F1, F6
transaction QNCX Common Stock Sale $390,626 -6,942 -93% $56.27* 523 07 Jul 2021 Direct F1, F7
transaction QNCX Common Stock Sale $29,806 -523 -100% $56.99* 0 07 Jul 2021 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QNCX Stock Option (right to buy) Options Exercise $0 -12,600 -9.5% $0.000000 119,752 06 Jul 2021 Common Stock 12,600 $2.23 Direct F9
transaction QNCX Stock Option (right to buy) Options Exercise $0 -17,400 -15% $0.000000 102,352 07 Jul 2021 Common Stock 17,400 $2.23 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.69 to $53.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.71 to $54.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.745 to $53.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.75 to $54.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.79 to $55.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.80 to $56.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.81 to $57.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F9 The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022.